Growth factors in angiogenesis: current interest and therapeutic potential.

Angiogenesis, the process of new blood vessel development, is an essential component of the body's physiology and contributes to the pathogenesis of a variety of diseases such as benign and malignant neoplasia and rheumatoid arthritis. Failure of this physiological response is also important in abnormalities of wound healing in diseases such as duodenal ulceration and diabetes. Angiogenesis is controlled by a variety of factors that initiate, control and terminate this complex, multi-stage process. This review covers those factors that are exciting much interest currently and have potential for incorporation into clinical medicine.

[1]  P. Steeg,et al.  Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines , 1994, International journal of cancer.

[2]  C W White,et al.  Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. , 1989, The New England journal of medicine.

[3]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Nishikawa,et al.  Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[6]  M. Burdick,et al.  Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. , 1995, Biochemical and biophysical research communications.

[7]  S. Mousa.  Angiogenesis promoters and inhibitors: potential therapeutic implications. , 1996, Molecular medicine today.

[8]  P. Colville-Nash,et al.  Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. , 1992, Annals of the rheumatic diseases.

[9]  G. Neufeld,et al.  Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[10]  P. Bornstein,et al.  Thrombospondins: structure and regulation of expression , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[12]  S. Szabó,et al.  Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. , 1994, Gastroenterology.

[13]  M. Kuzuya,et al.  Induction of angiogenesis by smooth muscle cell‐derived factor: Possible role in neovascularization in atherosclerotic plaque , 1995, Journal of cellular physiology.

[14]  E S Gragoudas,et al.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.

[15]  J. Isner,et al.  Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. , 1995, Circulation.

[16]  G. Neufeld,et al.  Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. , 1993, The Journal of clinical investigation.

[17]  V. Bautch,et al.  Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. , 1996, Cancer research.

[18]  S. Jimenez,et al.  Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[19]  S. Epstein,et al.  Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. , 1994, The American journal of physiology.

[20]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[21]  S. Abbot,et al.  Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression. , 1992, Arthritis and rheumatism.

[22]  J. Folkman,et al.  Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. , 1977, Microvascular research.

[23]  R. Strieter,et al.  THE ROLE OF CXC CHEMOKINES AS REGULATORS OF ANGIOGENESIS , 1995, Shock.

[24]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Hawkey,et al.  Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration. , 1995, Gut.

[26]  E. Sage,et al.  SPARC antagonizes the effect of basic fibroblast growth factor on the igration of bovine aortic endothelial cells , 1992, Journal of cellular biochemistry.

[27]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[28]  J. Folkman,et al.  gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice , 1995, The Journal of experimental medicine.

[29]  W. Risau,et al.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[31]  P. Colville-Nash,et al.  THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN A MURINE CHRONIC GRANULOMATOUS TISSUE AIR POUCH MODEL OF ANGIOGENESIS , 1996, The Journal of pathology.

[32]  V. Dixit,et al.  Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.

[33]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[34]  W. Risau,et al.  Angiogenic growth factors. , 1990, Progress in growth factor research.

[35]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[36]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[37]  J. Brown,et al.  The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. , 1995, The Journal of pharmacology and experimental therapeutics.

[38]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[39]  J. Slavin,et al.  Fibroblast growth factors: at the heart of angiogenesis. , 1995, Cell biology international.

[40]  J. Pearlman,et al.  Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis , 1995, Nature Medicine.

[41]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[42]  M. Iruela-Arispe,et al.  Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. , 1995, Molecular biology of the cell.

[43]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[44]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[45]  S. Funk,et al.  SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. , 1989, Journal of molecular and cellular cardiology.

[46]  M. Klagsbrun,et al.  Regulators of angiogenesis. , 1991, Annual review of physiology.

[47]  Shay Soker,et al.  VEGF/VPF: The angiogenesis factor found? , 1993, Current Biology.

[48]  Armen B. Shanafelt,et al.  The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.

[49]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[50]  J. Gamble,et al.  Angiogenesis: models and modulators. , 1995, International review of cytology.

[51]  T. Fan,et al.  Quantitative in-vivo studies on angiogenesis in a rat sponge model. , 1987, British journal of experimental pathology.

[52]  Sage Eh,et al.  Regulation of angiogenesis by extracellular matrix: the growth and the glue. , 1994 .

[53]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[54]  J. Folkman,et al.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.

[55]  D. Senger.  Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. , 1996, The American journal of pathology.